Xarelto indication stays as-is

Share this article:

Too little information—or, specifically, missing information, according to Bloomberg—prompted the FDA to reject Johnson & Johnson's request to expand the indication for the company's blood thinner Xarelto.

The drugmaker wanted the drug to be used to reduce blood clots in coronary artery disease patients. Friday's rejection marked a third miss for this indication.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.